2 results match your criteria [177lu]lu- dotazol

  • Page 1 of 1

Biodistribution and post-therapy dosimetric analysis of [Lu]Lu-DOTA in patients with osteoblastic metastases: first results.

EJNMMI Res 2019 Nov 28;9(1):102. Epub 2019 Nov 28.

Department of Nuclear Medicine, University Medical Center Bonn, Bonn, Germany.

Background: Preclinical biodistribution and dosimetric analysis of [Lu]Lu-DOTA suggest the bisphosphonate zoledronate as a promising new radiopharmaceutical for therapy of bone metastases. We evaluated biodistribution and normal organ absorbed doses resulting from therapeutic doses of [Lu]Lu-DOTA in patients with metastatic skeletal disease.

Method: Four patients with metastatic skeletal disease (age range, 64-83 years) secondary to metastatic castration-resistant prostate carcinoma or bronchial carcinoma were treated with a mean dose of 5968 ± 64 MBq (161. Read More

View Article and Full-Text PDF
November 2019

Evaluation of [Ac]Ac-DOTA for α-Therapy of Bone Metastases.

Curr Radiopharm 2018 ;11(3):223-230

Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, Germany.

Background: Conjugates of bisphosphonates with macrocyclic chelators possess high potential in bone targeted radionuclide imaging and therapy. DOTAZOL, zoledronic acid conjugated to DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), demonstrated promising results in vivo in small animals as well as in first patient applications using 68Ga for diagnosis via PET and the lowenergy β-emitter 177Lu for therapy of painful bone metastases. In consideration of the fact that targeted α-therapy probably offers various advantages over the use of β--emitters, the 225Ac-labelled derivative [225Ac]Ac-DOTAZOL was synthesized and evaluated in vivo. Read More

View Article and Full-Text PDF
January 2019
  • Page 1 of 1